|
|
 Previous Article | Table of Contents | Next Article 
Reinduction therapy in 297 children with acute lymphoblastic leukemia in
first bone marrow relapse: a Pediatric Oncology Group Study
GR Buchanan, GK Rivera, JM Boyett, AR Chauvenet, WM Crist and TJ Vietti
Department of Pediatrics, University of Texas Southwestern Medical Center,
Dallas 75235-9063.
Many children with acute lymphoblastic leukemia (ALL) develop a marrow
relapse during or shortly following initial continuation chemotherapy.
Achievement of a second complete remission is the initial step in a
successful retreatment effort. Reinduction results using two or three drugs
have been unsatisfactory, and previous reports of four-drug reinduction
programs have included relatively small numbers of patients. Pediatric
Oncology Group protocol 8303 was designed for patients with ALL in first
marrow relapse during or within 6 months after cessation of chemotherapy.
The results of reinduction therapy in 297 study patients are described
here. Four-drug reinduction therapy consisted of daily oral prednisone,
weekly vincristine and daunorubicin, and asparaginase three times weekly
for 4 weeks (PVDA). CNS retreatment consisted of two doses of triple
intrathecal chemotherapy. Of the 297 patients receiving reinduction, 245,
or 82%, entered second complete remission, six died of infection or
progressive disease, and 46 others still had M2 or M3 bone marrow status.
Forty of these latter patients received four doses (during a 2-week period)
of teniposide and cytarabine, after which 13 (32%) achieved complete
remission status. Thus, the overall second complete remission rate with
PVDA with or without teniposide/cytarabine was 258 of 297, or 87%. The
treatment program was generally well tolerated. Among the numerous factors
analyzed by using logistic regression, only female sex (P = .035), the
presence of blasts on the blood smear at the time of relapse (P = .0002),
and a length of initial complete remission less than 12 months (P = .021)
were independent predictors of failure to enter second remission. We
conclude that the intensive reinduction program described here is a highly
effective first step in the delivery of salvage therapy to patients with
ALL in first marrow relapse. The current challenge is to develop improved
continuation treatment for these children.
Volume 72,
Issue 4,
pp. 1286-1292,
10/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. A. Raetz, M. J. Borowitz, M. Devidas, S. B. Linda, S. P. Hunger, N. J. Winick, B. M. Camitta, P. S. Gaynon, and W. L. Carroll
Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
J. Clin. Oncol.,
August 20, 2008;
26(24):
3971 - 3978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Raetz, M. S. Cairo, M. J. Borowitz, S. M. Blaney, M. D. Krailo, T. A. Leil, J. M. Reid, D. M. Goldenberg, W. A. Wegener, W. L. Carroll, et al.
Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
J. Clin. Oncol.,
August 1, 2008;
26(22):
3756 - 3762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Kang, Y. H. Kang, B. Szymanska, U. Wilczynska-Kalak, M. A. Sheard, T. M. Harned, R. B. Lock, and C. P. Reynolds
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
Blood,
September 15, 2007;
110(6):
2057 - 2066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Berg, S. M. Blaney, M. Devidas, T. A. Lampkin, A. Murgo, M. Bernstein, A. Billett, J. Kurtzberg, G. Reaman, P. Gaynon, et al.
Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children's Oncology Group
J. Clin. Oncol.,
May 20, 2005;
23(15):
3376 - 3382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. C. Abshire, B. H. Pollock, A. L. Billett, P. Bradley, and G. R. Buchanan
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study
Blood,
September 1, 2000;
96(5):
1709 - 1715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Boulad, P. Steinherz, B. Reyes, G. Heller, A. P. Gillio, T. N. Small, J. A. Brochstein, N. A. Kernan, and R. J. O'Reilly
Allogeneic Bone Marrow Transplantation Versus Chemotherapy for the Treatment of Childhood Acute Lymphoblastic Leukemia in Second Remission: A Single-Institution Study
J. Clin. Oncol.,
January 1, 1999;
17(1):
197 - 197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Barrett, M. M. Horowitz, B. H. Pollock, M.-J. Zhang, M. M. Bortin, G. R. Buchanan, B. M. Camitta, J. Ochs, J. Graham-Pole, P. A. Rowlings, et al.
Bone Marrow Transplants from HLA-Identical Siblings as Compared with Chemotherapy for Children with Acute Lymphoblastic Leukemia in a Second Remission
N. Engl. J. Med.,
November 10, 1994;
331(19):
1253 - 1258.
[Abstract]
[Full Text]
|
|
|
|
|
